- Home
- FCT vs ACRV Comparison
FCT vs ACRV Comparison
Compare FCT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- ACRV
- Stock Information
- Founded
- FCT 2004
- ACRV 2018
- Country
- FCT United States
- ACRV United States
- Employees
- FCT N/A
- ACRV N/A
- Industry
- FCT Finance Companies
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FCT Finance
- ACRV Health Care
- Exchange
- FCT Nasdaq
- ACRV Nasdaq
- Market Cap
- FCT 268.9M
- ACRV 247.8M
- IPO Year
- FCT N/A
- ACRV 2022
- Fundamental
- Price
- FCT $10.37
- ACRV $6.44
- Analyst Decision
- FCT
- ACRV Strong Buy
- Analyst Count
- FCT 0
- ACRV 5
- Target Price
- FCT N/A
- ACRV $22.40
- AVG Volume (30 Days)
- FCT 106.8K
- ACRV 46.9K
- Earning Date
- FCT 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- FCT 11.29%
- ACRV N/A
- EPS Growth
- FCT N/A
- ACRV N/A
- EPS
- FCT N/A
- ACRV N/A
- Revenue
- FCT N/A
- ACRV N/A
- Revenue This Year
- FCT N/A
- ACRV N/A
- Revenue Next Year
- FCT N/A
- ACRV N/A
- P/E Ratio
- FCT N/A
- ACRV N/A
- Revenue Growth
- FCT N/A
- ACRV N/A
- 52 Week Low
- FCT $9.45
- ACRV $3.19
- 52 Week High
- FCT $10.42
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- FCT 54.03
- ACRV 31.95
- Support Level
- FCT $10.28
- ACRV $6.11
- Resistance Level
- FCT $10.38
- ACRV $8.35
- Average True Range (ATR)
- FCT 0.08
- ACRV 0.48
- MACD
- FCT 0.01
- ACRV -0.23
- Stochastic Oscillator
- FCT 84.00
- ACRV 12.55
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is the United States based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, the fund attempts to preserve capital. The fund seeks to achieve the objectives by investing in a portfolio of senior floating-rate loan interests. Its portfolio of investments consists of aerospace and defense, agricultural products, broadcasting, cable and satellite, electric utilities and other sectors.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.